OptiNose (NASDAQ: OPTN)
$5.30
(-6.4%)
-$0.36
Price as of January 10, 2025, 4:00 p.m. ET
OptiNose Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
OptiNose Company Info
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
News & Analysis
Featured Article
Why Sunnova Energy, Rimini Street, and OptiNose Stocks All Dropped Today
Some stock offerings dilute -- but not all.
Rich Smith | Aug 14, 2020
Featured Article
Here’s Why Shares of Optinose Crashed Today
A secondary offering resets the valuation of the ear, nose, and throat specialist.
Brian Orelli, PhD | Nov 21, 2019
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.